

Nivesh Portfolio Tracker

BALANCED

Risk Profile: MODERATE

AGGRESSIVE

Risk Profile: HIGH

CONSERVATIVE

Risk Profile: LOW



IndiaNivesh Securities Limited

Research Analyst SEBI Registration No. INH000000511

e-mail: research@indianivesh.in | Website: www.indianivesh.in

This is just a MODEL portfolio (not part of IndiaNivesh PMS)

Daljeet S. Kohli

Head of Research

Tel: +91 22 66188826

daljeet.kohli@indianivesh.in

Nivesh Model Portfolios Modifications

Please note the following changes made in our model portfolios:

Balanced Portfolio

Camlin Fine Sciences	Bought @ Rs 101 with target price of Rs.177
HIL	Book loss @ Rs 519 bought @ Rs 566

Reason: Rationale Attached

Reason: Termination of coverage –
Rationale Attached

Nivesh Portfolio | Balanced

Nivesh Portfolio Balanced			
Reset Date: 19/08/2014		Current Date: 09/02/2016	
Balanced	Seed capital Rs 10 Lakh	Benchmark BSE500	Risk Profile: MODERATE

Sr no	name Stock Name	Sector	Amt invested (Rs)	CMP (Rs)	Buy Date	Buy Price (Rs)	Qty Bought (Nos)	Target Price	MTM Gain/loss (Rs)
1	Torrent Pharmaceuticals Ltd	Pharma	100,000	1,327	21/8/2015	1636	61	1673	(18,915)
2	Infosys Ltd	IT	100,000	1,108	19/8/2014	890	112	1246	24,490
3	Camlin Fine Sciences Ltd	Speciality Chemicals	100,000	101	02/09/2016	101	995	177	-
4	Tata Motors Ltd	Auto	100,000	311	21/8/2015	330	303	496	(5,864)
5	Reliance Industries Ltd	Oil/gas/Energy	100,000	958	19/8/2014	1010	99	1300	(5,198)
6	Majeco Ltd	IT	100,000	545	21/8/2015	310	515	549	121,082
7	Lic Housing Finance Ltd	NBFC	100,000	424	21/8/2015	425	515	550	(361)
8	Aurobindo Pharma Ltd*	Pharma	100,000	743	3/3/2015	553	181	894	34,425
9	Hero Motocorp Ltd	Auto	100,000	2,581	19/8/2014	2533	39	2715	1,909
10	Karur Vysya Bank Ltd	Bank	100,000	448	19/8/2014	513	195	520	(12,661)

Total amount invested (Rs)	1,000,000
Cash in hand	
Profit (+)/Loss (-) Booked	159,615

Gain/loss (Rs)	298,523
Portfolio value (Rs)	1,298,523
Return on Investment (%)	29.9
Benchmark Return (%)	-3.6
Relative to Benchmark (%)	33.5

Note: * 1:1 Bonus Announced

Salient features of Balanced portfolio

- 1 Objective of this portfolio is to generate moderate returns in conjunction with moderate risk.
- 2 This portfolio is suitable for those investors whose risk appetite is moderate.
- 3 Stock selection criteria here will be strong fundamentals coupled with near term triggers
- 4 This is an equal weighted portfolio meaning equal amount of money is invested in the stocks selected in this portfolio
- 5 Benchmark index for calculating returns shall be BSE 500 Index
- 6 Total seed amount invested in the portfolio is Rs 10 lakh (Rs 1 lakh each in 10 stocks)
- 7 At any point of time total amount invested in portfolio will not be more than Rs 10 lakh
- 8 Profits generated will not be reinvested in the portfolio
- 9 This is a model portfolio reflecting INSL Research stocks preference at this point of time. Our views can change at any point of time & portfolio shall reflect the same accordingly.
- 10 This portfolio is not a part of PMS service provided by INSL. This is just a virtual (model) portfolio
- 11 Other products offered by INSL may have contradictory recommendation on stocks mentioned in this portfolio
- 12 All returns are from the date of inception of the portfolio

Nivesh Portfolio | Aggressive

Nivesh Portfolio Aggressive									
Reset Date: 19/08/2014			Current Date: 09/02/2016						
Aggressive		Seed Capital Rs 10 Lksh		Benchmark BSE500			Risk Profile : HIGH		

Sr no	Stock Name	Sector	Amt invested (Rs)	CMP (Rs)	Buy Date	Buy Price (Rs)	Qty Bought (Nos)	Target Price	MTM Gain/loss (Rs)
1	Pennar Industries Ltd	Iron & Steel	100,000	48	19/8/2014	52	1942	87	(6,893)
2	Kpr Mill Ltd	Textile	100,000	716	21/8/2015	712	140	1059	576
3	Icici Bank Ltd	Banks (Pvt)	100,000	209	19/8/2014	311	322	390	(32,582)
4	Glenmark Pharmaceuticals Ltd	Pharma	100,000	735	21/8/2015	1125	89	1163	(34,658)
5	Hsil Ltd	Ceramic Product	100,000	269	19/8/2014	290	345	396	(7,086)
6	Exide Industries Ltd	Auto ancillary	100,000	129	19/8/2014	167	599	200	(23,054)
7	Cipla Ltd	Pharma	100,000	556	21/8/2015	663	151	820	(16,161)
8	Meghmani Organics Ltd	Chemicals	100,000	22	19/8/2014	19	5263	34	14,737
9	Federal Bank Ltd*	Banks (Pvt)	100,000	45	19/8/2014	61	1653	82	(26,281)
10	Radico Khaitan Ltd	Liquor	100,000	108	19/8/2014	96	1042	165	11,979

Total amount invested (Rs)	1,000,000
Cash in hand	-
Profit (+)/Loss (-) Booked*	(2,678)

Gain/loss (Rs)	-122,101
Portfolio value (Rs)	877,899
Return on Investment (%)	-12.2
Benchmark Return (%)	-3.6
Relative to Benchmark (%)	-8.6

Note: * Federal Bank announced 1:1 Bonus

Salient features of Aggressive portfolio

- Objective of this portfolio is to generate moderate returns in conjunction with HIGH risk.
- This portfolio is suitable for those investors who like to take risk
- Stock selection criteria here will be fundamentals coupled with near term events, news flow or sheer momentum in stock price
- This is an equal weighted portfolio meaning equal amount of money is invested in the stocks selected in this portfolio
- Benchmark index for calculating returns shall be BSE 500 Index
- Total seed amount invested in the portfolio is Rs 10 lakh (Rs 1 lakh each in 10 stocks)
- At any point of time total amount invested in portfolio will not be more than Rs 10 lakh
- Profits generated will not be reinvested in the portfolio
- This is a model portfolio reflecting INSL Research stocks preference at this point of time. Our views can change at any point of time & portfolio shall reflect the same accordingly.
- This portfolio is not a part of PMS service provided by INSL. This is just a virtual (model) portfolio**
- Other products offered by INSL may have contradictory recommendation on stocks mentioned in this portfolio**
- All returns are from the date of inception of the portfolio

Nivesh Portfolio | Conservative

Nivesh Portfolio Conservative			
Reset Date: 19/08/2014	Current Date: 09/02/2016		
Conservative	Seed Capital Rs 10 Lakh	Benchmark BSE500	Risk Profile LOW

Sr no	Stock Name	Sector	Amt invested (Rs)	CMP (Rs)	Buy Date	Buy Price (Rs)	Qty Bought (Nos)	Target Price	MTM Gain/loss (Rs)
1	Shilpa Medicare Ltd	Pharma	100,000	426	19/8/2014	258	388	345	65,495
2	L&T Finance Holdings Ltd	BFSI	100,000	56	3/3/2015	69	1449	84	(19,493)
3	Nesco Ltd	Realty	100,000	1640	19/8/2014	1297	77	1680	26,446
4	Cadila Healthcare Ltd	Pharma	100,000	328	19/8/2014	236	424	454	39,249
5	Oil India Ltd	Oil/gas/Energy	100,000	339	19/8/2014	605	165	605	(43,950)
6	Capital First Ltd	Financial Services	100,000	403	19/8/2014	278	360	468	44,964
7	Divi'S Laboratories Ltd	Pharma	100,000	1034	21/8/2015	741	135	1358	39,588
8	Mangalam Cement Ltd	Cement	100,000	174	19/8/2014	238	420	376	(26,975)
9	Sqs India Bfsi Ltd#	IT	100,000	918	19/8/2014	466	215	665	96,996
10	Tata Global Beverages Ltd	FMCG	100,000	121	19/8/2014	156	641	180	(22,596)

Total amount invested (Rs)	1,000,000
Cash in hand	-
Profit (+)/Loss (-) Booked*	(71,795)

Gain/loss (Rs)	127,929
Portfolio value (Rs)	1,127,929
Return on Investment (%)	12.8
Benchmark Return (%)	-3.6
Relative to Benchmark (%)	16.4

(Formerly Thinksoft Global Services)

Salient features of Conservative portfolio

- Objective of this portfolio is to generate High returns in conjunction with low risk.
- This portfolio is suitable for those investors whose risk appetite is very low
- Stock selection criteria here will be strong business model, sustainable growth prospects likely to play in next few years
- This is an equal weighted portfolio meaning equal amount of money is invested in the stocks selected in this portfolio
- Benchmark index for calculating returns shall be BSE 500 Index
- Total seed amount invested in the portfolio is Rs 10 lakh (Rs 1 lakh each in 10 stocks)
- At any point of time total amount invested in portfolio will not be more than Rs 10 lakh
- Profits generated will not be reinvested in the portfolio
- This is a model portfolio reflecting INSL Research stocks preference at this point of time. Our views can change at any point of time & portfolio shall reflect the same accordingly.
- This portfolio is not a part of PMS service provided by INSL. This is just a virtual (model) portfolio**
- Other products offered by INSL may have contradictory recommendation on stocks mentioned in this portfolio**
- All returns are from the date of inception of the portfolio

HIL Ltd (Sell)

- HIL Ltd reported **disappointing Q3FY16 results**.
- HIL Ltd reported **net sales de-growth of 12.8% yoy** to reach Rs 2146 mn in Q3FY16 against Rs 2460 mn in Q3FY15 (vs. INSL est: Rs 2865 mn). This de-growth was due to de-growth of 11.7% yoy in building products segment (contributing 97.8% to sales). In our opinion, weak demand across the industry affected the performance of the company.
- **EBITDA missed our expectations** due to higher than expected raw material cost. EBITDA stood at Rs 54 mn in Q3FY16 against Rs 194 mn in Q3FY15 (vs. INSL est: 123 mn), signifying de-growth of 72.1% yoy. EBITDA margin contracted 536 bps yoy to reach 2.5% in Q3FY16 from 7.9% in Q3FY15. This was on account sales de-growth and higher raw material expenses. Raw material cost as percentage to sales increased to 59.8% in Q3FY16 from 52.4% in Q3FY15. On segmental front, building products segment (97.8% of revenue) reported EBIT margin of 2.2% against 8.1% in Q3FY15.
- **HIL reported net loss of Rs 3.9 mn** in Q3FY16 against profit of Rs 84 mn in Q3FY15. However, this was far lower than our expectation of profit of Rs 84 mn, primarily due to disappointing sales and EBITDA margin coupled with lower other income. Interest cost increased 64.3% yoy to reach Rs 32 mn in Q3FY16 from Rs 20 mn in Q3FY15. PAT adjusted for exceptional expense of VRS stood at loss of Rs 26 mn in Q3FY16 against Rs 75 mn in Q3FY15.
- **Outlook:** HIL Ltd has been reporting disappointing results since Q1FY16. Industry demand has been weak due to poor monsoon. Moreover, raw material cost has been increasing due to depreciating rupee and rising cement prices. The company imports chrysotile which is the key raw material for asbestos products. Due to weak demand players have not been able to pass on the raw material price increase to the consumers. In our opinion, this situation is similar to previous situation faced by industry in FY14. The outlook of the company would now depend on monsoon and rupee depreciation. If monsoon continues to be weak, then demand would further deteriorate and company would not be in a position to pass the raw material increase to consumers. In our opinion, investors should exit the stock till this situation changes. **We discontinue with estimates and recommend SELL on the stock.**

Camlin Fine Sciences Ltd. (CFSL)

CMP Rs.101 | EV/EBITDA (FY16E) 10.0x | EV/EBITDA (FY17E) 7.3x

Target Rs.177

Investment Rationale

- **Inorganic Action Created Significant Moat:** on back of technology acquisition from Borregaard Industries Ltd, Italy (Conglomerate - Orkla Group Co.), CFSL's management created significant technology moat around the business. Borregaard acquisition brought the technology to manufacture Diphenol, Hydroquinone, and Catechol. Additionally, the management successfully developed and commercially launched various downstream products of Diphenol like MEHQ, TBC, Veratrole, Catechol, and Guaiacol.
- **Emerging Blend Company:** Given the backward (Borregaard) and forward (DRESEN) integration CFSL is strongly positioned to enter into food formulations/food antioxidant blends industry. Additionally, leadership position in food grade antioxidants (TBHQ and BHA) and strong product pipeline Antioxidants & Aroma enhances the blending capabilities. In order to device customize solutions for clients, CFSL has started blending facilities in India, Europe, Brazil.
- **Dahej Capacity Margin Accretive:** The commencement of Dahej facility would improve sales-to-raw-material ratio further (EBITDA Margin 15% in FY15E to 21.9% in FY19E) along with significant expansion in revenue growth (48% Y/Y Revenue Growth in FY19E).

Valuation

At CMP of Rs.101, the stock is trading at EV/EBITDA multiple of 10.0x FY16E and 7.3x FY17E estimates. We value CFSL at EV/EBITDA multiple of 13.0x (Industry average 13.4x) FY17E and arrive at TP of Rs.177 (Ex. Dilution of Rs1500 mn) on the stock.

Y/E Mar (Rs. Mn)	Net Sales	Y/Y Ch %	PBDIT	EBITDA (%)	Adj PAT	Y/Y Ch %	EPS (Rs)	ROE (%)	ROCE	PE (x)	EV/EBITDA (x)
FY15A	5,583	9.8	838	15.0	547	90.4	5.7	40.5	31.0	17.5x	12.9x
FY16e	5,471	-2.0	1,089	19.9	535	-2.2	5.6	29.1	32.6	17.9x	10.0x
FY17e	7,495	37.0	1,492	19.9	855	59.9	8.9	32.2	34.3	11.2x	7.3x
FY18e	9,288	23.9	1,849	19.9	1,085	26.9	11.3	29.4	34.6	8.8x	5.9x
FY19e	13,754	48.1	3,013	21.9	1,926	77.5	20.1	34.5	35.6	5.0x	3.6x